labetalol has been researched along with Fasting Hypoglycemia in 9 studies
Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.
labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.
2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.
Fasting Hypoglycemia: HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.
| Excerpt | Relevance | Reference |
|---|---|---|
| "02; 2--A more frequent adjustment of daily dosage with MD (n = 15) than with ACE (n = 10) or LAB (n = 7); 3--The absence of any significant difference for uricemia level, platelet counts, foetal cardiac rythm, and occurrence of pre-eclampsia (MD = 4; ACE = 3; LAB = 4; 4--An equivalent birth-weight (MD = 3110 +/- 628 g; ACE = 3115 +/- 645." | 6.66 | [Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol]. ( Blazquez, G; Gérard, J; Lardoux, H; Leperlier, E, 1988) |
| "The results of the treatment in hypertension with pregnancy by a alpha-beta blocker in 58 women show: the good tolerance of the drug and its lack of teratogenic effect, its quasi-constant efficiency (91%) in hypertension, its benefit repercussion on neonatal weight." | 5.27 | [Treatment of arterial hypertension in pregnancy with an alpha-beta blocker. 58 Cases treated with labetalol]. ( Blazquez, G; Gérard, J; Giraud, P; Jeuffroy, A; Lardoux, H; Mounac, M, 1984) |
| "Our findings suggest that neonates born to mothers exposed to β blockers in late pregnancy, including labetalol, are at elevated risk for neonatal hypoglycemia and bradycardia." | 3.83 | Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia. ( Bateman, BT; Desai, RJ; Fischer, MA; Hernandez-Diaz, S; Huybrechts, KF; Maeda, A; Mogun, H; Patorno, E; Seely, EW, 2016) |
| "A single 30 mg intravenous dose of labetalol given 20 minutes prior to cesarean delivery at 35 weeks of gestation for severe pregnancy-induced hypertension was associated with symptoms of beta-adrenergic blockade (hypoglycemia, bradycardia, hypotension) in preterm twins." | 3.69 | Neonatal adrenergic blockade following single dose maternal labetalol administration. ( Bhatt-Mehta, V; Donn, SM; Klarr, JM, 1994) |
| "Forty eight neonates, born to mothers suffering from pregnancy induced hypertension and receiving labetalol for control of blood pressure, were studied for the possible adverse effects of the drug." | 3.68 | Effects of maternal labetalol on the newborn infant. ( Deorari, AK; Munshi, UK; Paul, VK; Singh, M, 1992) |
| "02; 2--A more frequent adjustment of daily dosage with MD (n = 15) than with ACE (n = 10) or LAB (n = 7); 3--The absence of any significant difference for uricemia level, platelet counts, foetal cardiac rythm, and occurrence of pre-eclampsia (MD = 4; ACE = 3; LAB = 4; 4--An equivalent birth-weight (MD = 3110 +/- 628 g; ACE = 3115 +/- 645." | 2.66 | [Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol]. ( Blazquez, G; Gérard, J; Lardoux, H; Leperlier, E, 1988) |
| "The results of the treatment in hypertension with pregnancy by a alpha-beta blocker in 58 women show: the good tolerance of the drug and its lack of teratogenic effect, its quasi-constant efficiency (91%) in hypertension, its benefit repercussion on neonatal weight." | 1.27 | [Treatment of arterial hypertension in pregnancy with an alpha-beta blocker. 58 Cases treated with labetalol]. ( Blazquez, G; Gérard, J; Giraud, P; Jeuffroy, A; Lardoux, H; Mounac, M, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 2 (22.22) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zullo, AR | 1 |
| Hersey, M | 1 |
| Lee, Y | 1 |
| Sharmin, S | 1 |
| Bosco, E | 1 |
| Daiello, LA | 1 |
| Shah, NR | 1 |
| Mor, V | 1 |
| Boscardin, WJ | 1 |
| Berard-Collins, CM | 1 |
| Dore, DD | 1 |
| Steinman, MA | 1 |
| Bateman, BT | 1 |
| Patorno, E | 1 |
| Desai, RJ | 1 |
| Seely, EW | 1 |
| Mogun, H | 1 |
| Maeda, A | 1 |
| Fischer, MA | 1 |
| Hernandez-Diaz, S | 1 |
| Huybrechts, KF | 1 |
| Immanni, S | 1 |
| Khan, EI | 1 |
| Staunton, M | 1 |
| Daskas, N | 1 |
| Crowne, E | 1 |
| Shield, JP | 1 |
| Gérard, J | 2 |
| Blazquez, G | 2 |
| Mounac, M | 1 |
| Giraud, P | 1 |
| Jeuffroy, A | 1 |
| Lardoux, H | 2 |
| Klarr, JM | 1 |
| Bhatt-Mehta, V | 1 |
| Donn, SM | 1 |
| Munshi, UK | 1 |
| Deorari, AK | 1 |
| Paul, VK | 1 |
| Singh, M | 1 |
| Odugbesan, O | 1 |
| Toop, M | 1 |
| Barnett, AH | 1 |
| Leperlier, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Propranolol as a Treatment for Impaired Awareness of Hypoglycemia in Type 1 Diabetes[NCT03161964] | Phase 2 | 2 participants (Actual) | Interventional | 2017-10-19 | Terminated (stopped due to Statistical power could not be achieved due to low enrollment.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for labetalol and Fasting Hypoglycemia
| Article | Year |
|---|---|
Beta-and alpha-adrenergic blockade and metabolic responses to insulin induced hypoglycaemia in diabetics.
Topics: Blood Glucose; Blood Pressure; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Fatty Acids, Non | 1987 |
[Randomized, comparative study on the treatment of moderate arterial hypertension during pregnancy: methyldopa, acebutolol, labetalol].
Topics: Acebutolol; Adult; Female; Heart Rate, Fetal; Humans; Hypertension; Hypoglycemia; Infant, Newborn; L | 1988 |
7 other studies available for labetalol and Fasting Hypoglycemia
| Article | Year |
|---|---|
Outcomes of "diabetes-friendly" vs "diabetes-unfriendly" β-blockers in older nursing home residents with diabetes after acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged, 80 and over; Blood Glucose; Carvedilol; Diabetes Mellitus, Type 2 | 2018 |
Late Pregnancy β Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia.
Topics: Adrenergic beta-Antagonists; Atenolol; Bradycardia; Cohort Studies; Female; Humans; Hypertension; Hy | 2016 |
Hypoglycaemia secondary to labetalol infusion.
Topics: Adult; Antihypertensive Agents; Female; Humans; Hypoglycemia; Infusions, Intravenous; Labetalol; Pre | 2011 |
Is labetalol really a culprit in neonatal hypoglycaemia?
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Female; Humans; Hypertension; Hypoglycemia; In | 2013 |
[Treatment of arterial hypertension in pregnancy with an alpha-beta blocker. 58 Cases treated with labetalol].
Topics: Adrenergic beta-Antagonists; Adult; Ethanolamines; Female; Fetal Diseases; Humans; Hypertension; Hyp | 1984 |
Neonatal adrenergic blockade following single dose maternal labetalol administration.
Topics: Adult; Bradycardia; Diseases in Twins; Female; Fetal Blood; Humans; Hypoglycemia; Hypotension; Infan | 1994 |
Effects of maternal labetalol on the newborn infant.
Topics: Asphyxia Neonatorum; Female; Fetal Growth Retardation; Humans; Hypertension; Hypoglycemia; Incidence | 1992 |